Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones

Antiviral Therapy

Volumn 12, Issue 1, 2007, Pages 1-6

  Ali, Syed Hamid ^a   Chandraker, Anil ^b   DeCaprio, James A ^c  

^a AGA KHAN UNIVERSITY   (Pakistan)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE IV; HELICASE; LEVOFLOXACIN; NALIDIXIC ACID; OFLOXACIN; QUINOLONE DERIVATIVE; TROVAFLOXACIN; VIRUS T ANTIGEN;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA REPLICATION; DNA TUMOR VIRUS; DNA VIRUS; DRUG POTENCY; ENZYME INHIBITION; FLOW CYTOMETRY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RNA VIRUS; SIMIAN VIRUS 40; VIRUS INHIBITION;

ANTIGENS, POLYOMAVIRUS TRANSFORMING; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CIPROFLOXACIN; CYTOPATHOGENIC EFFECT, VIRAL; DNA HELICASES; DNA REPLICATION; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLUOROQUINOLONES; HUMANS; NAPHTHYRIDINES; OFLOXACIN; PLAQUE ASSAY; REPRODUCIBILITY OF RESULTS; SIMIAN VIRUS 40; TIME FACTORS; VIRUS REPLICATION;

EID: 33847347546     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Simmons DT. SV40 large T antigen functions in DNA replication and transformation. Adv Virus Res 2000; 55:75-134.
2. Caputo A, Barbanti-Brodano G, Wang E, Ricciardi RP. Transactivation of BKV and SV40 early promoters by BKV and SV40 T-antigens. Virology 1986; 152:459-465.
3. Tavis JE, Frisque RJ. Altered DNA binding and replication activities of JC virus T-antigen mutants. Virology 1991; 183:239-250.
4. Josephson MA, Williams JW, Chandraker A, Randhawa PS. Polyomavirus-associated nephropathy: update on antiviral strategies. Transpl Infect Dis 2006; 8:95-101.
5. Kojima H, Kaita KD, Hawkins K, Uhanova J, Minuk GY. Use of fluoroquinolones in patients with chronic hepatitis C virus-induced liver failure. Antimicrob Agents Chemother 2002; 46:3280-3282.
6. Negro F, Male PJ, Perrin L, Giostra E, Hadengue A. Treatment of chronic hepatitis C with alpha-interferon plus ofloxacin in patients not responding to alpha-interferon alone. J Hepatol 1998; 29:369-374.
7. Richter SN, Palu G. Inhibitors of HIV-1 Tat-mediated transactivation. Curr Med Chem 2006; 13:1305-1315.
8. Portolani M, Pietrosemoli P, Cermelli C, et al. Suppression of BK virus replication and cytopathic effect by inhibitors of prokaryotic DNA gyrase. Antiviral Res 1988; 9:205-218.
9. Higgins PG, Fluit AC, Schmitz FJ. Fluoroquinolones: structure and target sites. Curr Drug Targets 2003; 4:181-190.
10. Sugino A, Higgins NP, Brown PO, Peebles CL, Cozzarelli NR. Energy coupling in DNA gyrase and the mechanism of action of novobiocin. Proc Natl Acad Sci USA 1978; 75:4838-4842.
11. Kreuzer KN, Cozzarelli NR. Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth. J Bacteriol 1979; 140:424-435.
12. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 1995; 270:21429-21432.
13. Reece RJ, Maxwell A. DNA gyrase: structure and function. Crit Rev Biochem Mol Biol 1991; 26:335-375.
14. Levine C, Hiasa H, Marians KJ. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim Biophys Acta 1998; 1400:29-43.
15. Wang JC. Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine. Q Rev Biophys 1998; 31:107-144.
16. Marians KJ. Crawling and wiggling on DNA: structural insights to the mechanism of DNA unwinding by helicases. Structure Fold Des 2000; 8:R227-235.
17. Morais Cabral JH, Jackson AP, Smith CV, Shikotra N, Maxwell A, Liddington RC. Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 1997; 388:903-906.
18. Li D, Zhao R, Lilyestrom W, et al. Structure of the replicative helicase of the oncoprotein SV40 large tumour antigen. Nature 2003; 423:512-518.
19. Singleton MR, Sawaya MR, Ellenberger T, Wigley DB. Crystal structure of T7 gene 4 ring helicase indicates a mechanism for sequential hydrolysis of nucleotides. Cell 2000; 101:589-600.
20. Shen LL, Pernet AG. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA. Proc Natl Acad Sci USA 1985; 82:307-311.
21. Shen LL, Mitscher LA, Sharma PN, et al. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug-DNA binding model. Biochemistry 1989; 28:3886-3894.
22. Richter S, Parolin C, Palumbo M, Palu G. Antiviral properties of quinolone-based drugs. Curr Drug Targets Infect Disord 2004; 4:111-116.